Clinical Trials on Military Operations in Japan
Total 62 results
-
GlaxoSmithKlineActive, not recruitingPruritusUnited States, France, Spain, Israel, Belgium, Canada, Czechia, Italy, United Kingdom, China, Germany, Mexico, Japan, Brazil, Poland, Russian Federation, Greece, Argentina, Switzerland, Bulgaria
-
Boehringer IngelheimRecruitingLung Neoplasms | Pancreatic Neoplasms | Bladder Cancer | Solid Tumors | Biliary Tract CancerUnited States, Korea, Republic of, Spain, Australia, Japan, Germany, Taiwan, Singapore, Thailand, France, Belgium, Austria, Switzerland, United Kingdom, South Africa
-
AbbVieRecruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell CarcinomaUnited States, Israel, Japan, Puerto Rico, Korea, Republic of, Taiwan
-
AstraZenecaDaiichi SankyoRecruitingGastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate CancerSpain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
-
Gilead SciencesTerminatedPrimary Sclerosing CholangitisUnited States, Belgium, Israel, Spain, United Kingdom, Australia, Germany, New Zealand, Denmark, France, Japan, Switzerland, Austria, Canada, Finland, Italy
-
Merck Sharp & Dohme LLCActive, not recruitingBiliary Tract CarcinomaUnited States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Spain, Taiwan, Thailand, Turkey, United Kingdom
-
Seagen Inc.Active, not recruitingUrologic Neoplasms | Uterine Cervical Neoplasms | Uterine Neoplasms | Carcinoma, Non-Small-Cell Lung | Biliary Tract Neoplasms | HER2 Mutations Breast NeoplasmsUnited States, United Kingdom, Spain, Korea, Republic of, Italy, Belgium, Germany, Japan, Netherlands, Poland
-
Eli Lilly and CompanyMerck Sharp & Dohme LLC; Loxo Oncology, Inc.RecruitingCarcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Biliary Tract NeoplasmsCanada, United States, Japan, Australia, France, Korea, Republic of
-
AstraZenecaRecruitingBreast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract CarcinomaUnited States, Australia, Spain, United Kingdom, Korea, Republic of, Canada, Italy, Poland, Belgium, China, Japan, Taiwan, Thailand, Hungary, Netherlands
-
Merck Sharp & Dohme LLCRecruitingUterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Hepatocellular Carcinoma | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder NeoplasmsUnited States, Chile, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, Turkey, Canada
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerCanada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
-
AstraZenecaRecruitingCervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5Canada, China, Spain, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia